Navigation Links
caprotec bioanalytics Announces Commercial Launch of Three New caproKits™ for Applications in Functional Proteomics and Drug Development

BERLIN and BURLINGTON, Mass., Sept. 30 /PRNewswire/ -- caprotec bioanalytics GmbH announced today the commercial launch of three new caproKits™, enabling the discovery, identification and characterization of proteins for applications in functional proteomics and drug development.

The three new kits are the Dasatinib caproKit, the C2 CAMP caproKit and the Biotin Capping Kit. Together, these new kits increase the number of commercially available caproKits to a total of 10.

The company's caproKits are based on the proprietary Capture Compound Mass Spectrometry (CCMS) technology, a novel and direct way to investigate small molecule–protein interactions resulting in a significant functional reduction of proteome complexity. Capture Compounds™ enable the direct isolation and identification of defined protein classes, including membrane proteins, out of complex biological samples.  

The new and existing caproKits target different areas of research ranging from signal transduction to epigenetics and proteases. The Dasatinib and C2 cAMP caproKits are the newest additions to the company's signal transduction product line. The Biotin Capping Kit is used to improve analytical performance by decreasing background noise when study samples contain a high amount of naturally biotin-modified proteins.  caproKits are versatile reagents and can be broadly used across different species and sources of sample material. Additional caproKits for applications in other research areas are under development and will be released in the coming months.

"We are pleased to now offer a broad suite of products specifically for kinases and nucleotide binding proteins, both being of paramount importance in signal transduction and drug discovery research," stated Dr. Hubert Koster, CEO of caprotec bioanalytics.  "Our new caproKits are innovative and effective chemical proteomics tools for researchers in need of a solution for targeted reduction of sample complexity."

About caprotec bioanalytics GmbH

caprotec bioanalytics is headquartered in Berlin, Germany with a US subsidiary in Burlington, MA. The company focuses on the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology. The core of the CCMS technology consists of small, tri-functional molecules called Capture Compounds™. They enable a targeted isolation of proteins directly from complex biological samples. After isolation the captured proteins are identified and characterized by mass spectrometry or gel electrophoresis and Western blotting. Providing a state-of-the-art platform for the isolation and analysis of proteins from complex mixtures, the CCMS technology has enormous potential in proteomics, drug development and the development of biomarkers. The technology is protected by a broad patent portfolio.

SOURCE caprotec bioanalytics GmbH
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. caprotec bioanalytics Announces the Successful Completion of a Collaborative Research Project With Roche
2. Jiangbo Pharmaceuticals Announces Fourth Quarter and Fiscal Year 2010 Results
3. Repligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression
4. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
5. BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock
6. UPDATE - ProUroCare Announces $3 Million Financing Agreement
7. Ascension Orthopedics Announces First Implantations of TITAN™ Modular Shoulder
8. DePuy Hip Recall & Avandia Focus of Nov. 3 Conference, HB Announces
9. CVS Caremark Announces 2010 Analyst Day
10. MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
11. Sun Pharma Announces Expiration of Subsequent Offering Period
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced ... Outlook to 2019 - Rise in Cardiac Disorders and Growing ... to their offering. Boston ... scientific and others. --> The market ... Boston scientific and others. ...
(Date:11/26/2015)... Nov. 26, 2015 Research and Markets ... the "2016 Future Horizons and Growth Strategies ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging ... --> --> This ... the Japanese therapeutic drug monitoring market, including emerging ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The print component of “Supporting ... Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of approximately 250,000 ... through a vast social media strategy and across a network of top news ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its ... exclusive list of CAAHEP accredited colleges, as only one of twelve colleges and universities ...
Breaking Medicine News(10 mins):